Auauniversity

Appropriate Use of Genetic Testing (who, what, when and how?) CME Available: auau.auanet.org/node/41734 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications. 2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration. 3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.

Treatment Intensification in Metastatic HSPC CME Available: https://auau.auanet.org/node/41733 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology.  2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks.  3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.

Sequencing Of Agents CME Available: auau.auanet.org/node/41735 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials. 3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance. 4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.

Non-Muscle Invasive Bladder Cancer: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41961 After participating in this CME activity, participants will be able to: 1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions. 2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. 3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC. 4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies. 5. Properly manage adverse events associated with NMIBC treatment. Acknowledgements Support provided by an independent educational grant from: ImmunityBio, Inc. Merck & Co., Inc. UroGen Pharma, Inc.

Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/42040 After participating in this CME activity, participants will be able to: 1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy. 2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes. 3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma. 4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management. 5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes. Acknowledgements Support provided by an independent educational

Complex Cases in Kidney Stone Disease CME Available: https://auau.auanet.org/node/41889 At the conclusion of this activity, participants will be able to: 1. Describe the pathophysiology, genetic basis, and clinical presentation of Primary Hyperoxaluria Type 1. 2. Analyze the unique considerations and challenges in evaluating kidney stones in pediatric patients. 3. Utilize the results of 24-hour urine testing to guide dietary and pharmacologic interventions for stone prevention. 4. Recognize the indications for genetic testing in patients with kidney stones and utilize the results to inform diagnosis and treatment. 5. Employ appropriate patient management and family counseling strategies in consideration of the impact of genetic testing results. 6. Properly refer patients with kidney stone disease to a nephrologist when warranted. ACKNOWLEDGEMENTS: Support provided by an independent educational grant from:  Alnylam Pharmaceuticals, Inc.

Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24

AUA2024: Journal of Urology Lecture: Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color Presenter: Quoc-Dien Trinh, MD, MBA

AUA2024: Ramon Guiteras Lecture: Modern Innovation: Promise or Peril? Presenter: Craig Niederberger, MD, FACS

AUA Leadership and Business Podcast: Urology Practice Manage - Overcoming Operational Challenges This episode is brought to you by the AUA Leadership and Business Podcast, where urologic professionals experience the practical application of business acumen essential to successfully navigating today’s rapidly changing business environment! Subscribe today via your favorite podcast app.

Focal Therapy Options for Prostate Cancer AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS, FRCS(Glasg) Guest: Ruben Olivares, MD Outline: Segment 1: Why Focal Therapy? Segment 2: Patient selection for Focal Therapy Segment 3: Review of Existing Focal Therapy Modalities Segment 4: How to Build a Successful Focal Therapy Program

Hereditary Kidney Cancer Syndromes CME Available: https://auau.auanet.org/node/41772 ACKNOWLEDGEMENTS: Support provided by an independent educational grant from:  Merck & Co., Inc.  LEARNING OBJECTIVES: At the conclusion of this activity, participants should be able to: 1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation. 2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members. 3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors. 4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies. 5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.

Prostate Cancer Update (2024): Expert Guidance for Urologists CME Available: https://auau.auanet.org/node/41868 Acknowledgements Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc. Learning Objectives At the conclusion of this activity, the learner will: 1. Align their practice with current AUA Guidelines (and recent amendments) pertaining to Screening, Diagnosis, and Management of Prostate Cancer. 2. Determine appropriate use of biomarker testing as it relates to diagnosis and therapy. 3. Analyze the role of imaging and types of imaging that aid in staging patients with prostate cancer. 4. Implement appropriate treatment paradigms for metastatic prostate cancer including treatment intensification. 5. Discuss the role of genetic and molecular profiling in the personalization of prostate cancer treatment plans.

Treatment Intensification in Metastatic HSPC CME Available: https://auau.auanet.org/node/41733 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology.  2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks.  3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.

Appropriate Use of Genetic Testing (who, what, when and how?) CME Available: https://auau.auanet.org/node/41734 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications. 2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration. 3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.

Sequencing Of Agents CME Available: https://auau.auanet.org/node/41735 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials. 3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance. 4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.

Urologic Oncology: Genetics And Genomics AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS, FRCS(Glasg) Guest: Hong Truong, MD, MS Outline: Segment 1: Genetics 101 – How Genes Influence Cancer Risk Segment 2: Genetic Risk Assessment Segment 3: Genetics of Kidney Cancer Segment 4: Genetics of Upper Tract Cancer Segment 5: Genetics of Prostate Cancer

Biomarkers and Molecular Imaging for Prostate Cancer CME Available: https://auau.auanet.org/node/41727 ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Lantheus Medical Imaging Novartis Pharmaceuticals Corporation LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers. 2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring. 3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.

Kidney Cancer & SBRT in the Management of RCC AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS, FRCS(Glasg) Guest: Daniel Shapiro, MD Outline: Segment 1: History of radiation therapy in renal cell carcinoma Segment 2: Radiation use in the setting of primary kidney tumors Segment 3: Radiation use for locally advanced tumors including tumor thrombi Segment 4: Radiation therapy for metastatic disease Segment 5: Limitations of radiation therapy and selecting patients for radiation therapy

Pediatric Urology: Differences of Sex Development AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS, FRCS(Glasg) Guest: Emilie Johnson, MD, MPH, FACS, FAAP Outline: Segment 1: DSD Nomenclature – Words Matter! Segment 2: Multidisciplinary Care Model Segment 3: Example Conditions Segment 4: Approach to Prenatal and Early Postnatal Care Segment 5: Gonadal Management – also evolving